Neuropsychiatric disorders in patients with heart failure: not to be ignored

Manolis, Theodora A.; Manolis, Antonis A.; Melita, Helen; Manolis, Antonis S.

doi:10.1007/s10741-022-10290-2

Cited by 8 publications

(4 citation statements)

References 240 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ukoliko se POKPi klinički manifestiraju, obilježeni su poreme ćajem pamćenja, učenja, koncentracije, govornog izra žavanja, psihomotorne brzine, izvršnih funkcija, ali i mentalnim, psihološkim i emocionalnim promjenama kod bolesnika. 6,7 Pojava POKPa potiče nastanak dru gih poslijeoperacijskih komplikacija, razvoj demenci je, produljuje bolnički oporavak i povisuje periopera cijski mortalitet. Učestale su potrebe za rehabilitaci jom, te u konačnici može doći do gubitka radne spo sobnosti i nužnosti za prijevremenim umirovljenjem.…”

Section: Discussionunclassified

The pathogenesis of cognitive decline after cardiac surgery: A Narrative Review

2023

View full text Add to dashboard Cite

Section: Discussionunclassified

The pathogenesis of cognitive decline after cardiac surgery: A Narrative Review

2023

View full text Add to dashboard Cite

“…Often, patients do not have resources for post-stroke rehabilitation treatments, or still do not have access, as such treatments are only available in medium-complexity services, requiring displacement. All of these factors contribute to the high frequency of depression and anxiety disorders, which draws attention to the possible consequences that can result if patients are not identifi ed and treated appropriately, even when the functional impact of stroke in patients is mild [62,64].…”

Section: Usa Revisionmentioning

confidence: 99%

Ischemic Stroke of Cardioembolic Origin Systematic Review

Ammar¹,

Lopes²,

Lopes³

et al. 2023

J Biomed Res Environ Sci

View full text Add to dashboard Cite

Ischemic stroke corresponds to 80% of cases in Brazil, which demonstrates the epidemiological importance in Brazil. The magnitude of this fact reflects the reason why stroke is considered the second cause of death in the world, and the first cause of death in Brazil, in addition to being the second cause of cognitive losses. The main causes that favor the occurrence of ischemic stroke determine the situation of risk groups. Such factors can be classified as modifiable, non-modifiable and potential risk group.

show abstract

“…Currently, treatment aims to ease the impact of these symptoms on daily life activities of patients and improve the quality of life. However, studies have shown that > 50% of patients with CHF develop anxiety and depression (A&D) symptoms[ 2 , 3 ], which has been associated with unfavorable outcomes, such as increased CHF-related hospitalization and mortality rates. However, distinguishing whether certain symptoms are related to A&D or are symptoms of CHF remains a challenge.…”

Section: Introductionmentioning

confidence: 99%

Assessing myocardial indices and inflammatory factors to determine anxiety and depression severity in patients with chronic heart failure

Zhang,

Wang,

Cui

et al. 2024

World J Psychiatry

View full text Add to dashboard Cite

BACKGROUND Patients with chronic heart failure (CHF) have a progressive disease that is associated with poor quality of life and high mortality. Many patients experience anxiety and depression (A&D) symptoms, which can further accelerate disease progression. We hypothesized that indicators of myocardial function and inflammatory stress may reflect the severity of A&D symptoms in patients with CHF. Changes in these biomarkers could potentially predict whether A&D symptoms will deteriorate further in these individuals. AIM To measure changes in cardiac and inflammatory markers in patients with CHF to determine A&D severity and predict outcomes. METHODS We retrospectively analyzed 233 patients with CHF treated at the Jingzhou Hospital, Yangtze University between 2018-2022 and grouped them according to Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) scores. We compared clinical data in the no-A&D, mild-A&D, moderate-A&D, and severe-A&D groups, the SAS and SDS scores with the New York Heart Association (NYHA) functional classification, and cardiac markers and inflammatory factors between the no/mild-A&D and moderate/severe-A&D groups. Regression analysis was performed on the markers with P < 0.05 to determine their ability to predict A&D severity in patients and the area under the receiver operating characteristic curve (AUROC) was used to evaluate their accuracy. RESULTS In the inter-group comparison, the following variables had an effect on A&D severity in patients with CHF: NYHA class, left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter, N-terminal pro-brain natriuretic peptide (NT-proBNP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (P < 0.05). Other variables did not differ significantly between the A&D groups (P > 0.05). In addition, we found that higher NYHA classes were associated with higher the SAS and SDS scores (P < 0.05). Regression analysis showed that LVEF, NT-proBNP, and IL-6 were independent risk factors for A&D severity (P < 0.05). Among them, NT-proBNP had the best predictive ability as a single indicator (AUROC = 0.781). Furthermore, the combination of these three indicators exhibited a good predictive effect toward discriminating the extent of A&D severity among patients (AUROC = 0.875). CONCLUSION Cardiac and inflammatory biomarkers, such as LVEF, NT-proBNP, and IL-6, are correlated with A&D severity in patients with CHF and have predictive value.

show abstract

Neuropsychiatric disorders in patients with heart failure: not to be ignored

Cited by 8 publications

References 240 publications

The pathogenesis of cognitive decline after cardiac surgery: A Narrative Review

The pathogenesis of cognitive decline after cardiac surgery: A Narrative Review

Ischemic Stroke of Cardioembolic Origin Systematic Review

Assessing myocardial indices and inflammatory factors to determine anxiety and depression severity in patients with chronic heart failure

Contact Info

Product

Resources

About